Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Vical completes SPA for Allovectin-7

Feb. 14, 2005

Boehringer Ingelheim discontinues development of bivatuzumab mertansine

Feb. 14, 2005

Positive findings in phase II study of ProMune plus chemotherapy in NSCLC

Feb. 14, 2005

Update on the pharmacokinetics and safety of Virulizin in pancreatic cancer

Feb. 11, 2005

U. of Pittsburgh to support development of NK cell therapy for cancer

Feb. 10, 2005

Preclinical data affirms anticancer properties of adecatumumab

Feb. 10, 2005

Viragen seeks expansion of approval for Multiferon in Sweden

Feb. 9, 2005

Proxinium awarded orphan drug status for recurrent head and neck cancer

Feb. 8, 2005

Xcyte withdraws phase II/III protocol in chronic lymphocytic leukemia

Feb. 7, 2005

1D09C3 enters phase I in B-cell lymphoma patients

Feb. 3, 2005

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026